Prednisone plus cyclophosphamide therapy for IgA nephropathy patients with impaired renal function and nephrotic syndrome

LI Ya,WANG Weiming,REN Hong,ZHANG Wen,SHEN Pingyan,WANG Zhaohui,LI Xiao,JIA Xiaoyuan,CHEN Nan

2012-01-01

Abstract:Objective To compare the clinical outcomes of prednisone therapy with prednisone plus cyclophosphamide therapy for IgA nephropathy (IgAN) combined with impaired renal function and nephrotic syndrome. Methods A total of 110 patients with renal biopsy-proven IgAN and nephrotic syndrome in Shanghai Ruijin Hospital from January 2004 to May 2010 were enrolled in this study. The patients were divided into steroid group (n=55, eGFR<70 mL·min-1·1.73 m-2 in 29 and eGFR>70 mL·min-1·1.73 m-2 in 26) and prednisone plus cyclophosphamide group (n=55, eGFR<70 mL·min-1·1.73 m-2 in 32 and eGFR>70 mL·min-1·1.73 m-2 in 23). Prednisone usage: 0.8-1 mg·kg-1·d-1 for 12 weeks, then decresed 10%-15% every 3 or 4 weeks until 10-15 mg/d for another 24 weeks. Cyclophosphamide usage: 0.5-0.75 g/m2, every 4 weeks for 6 times, then every 8 weeks for 3 times. ACEI or ARB could be used in hypertension patients. The mean follow-up period was 36 months. Serum albumin, 24-hour proteinuria and serum creatinine were monitored. Clinical baseline data and histological findings of two groups were compared. Results There were no significant differences in terms of age, gender, hypertension, hematuria, seralbumin, 24-hour proteinuria or serum creatinine between the two groups with various GFR before treatment (all P>0.05). Neither were the incidences of balloon sclerosis, mesangial hyperplasia, crescent formation, interstitial sclerosis, tubular atrophy or vascular lesions (all P>0.05). Serum albumin was significantly increased and 24-hour proteinuria was significantly decreased in all IgAN patients at 3 months after treatment (P<0.05). There was no significant difference of the level of serum creatinine before and after treatment in the patients with eGFR<70 mL·min-1·1.73 m-2 in the steroid group. However, in the cyclophosphamide group, the level of serum creatinine at the final follow-up was significantly higher than the baseline level (all P<0.05). The levels of serum creatinine before and after treatment were not significantly changed in patients with eGFR>70 mL·min-1·1.73 m-2 in either of the groups (all P>0.05). In steroid group, two patients had abnormal glucose tolerance, which was improved after steroid reduction; one patient suffered from liver damage and liver function became normal after treatment. In steroid plus cyclophosphamide group, one case had osteoporosis and 2 had abnormal glucose tolerance. No severe infections or other adverse reactions occurred in the patients of the two groups. Conclusion Both steroid therapy and cytotoxic medication can effectively reduce proteinuria in IgAN patients with impaired renal function. But there is no adequate evidence that cyclophosphamide is beneficial to the IgAN prognosis and can slow down renal function decline.